Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Matthew J. Ellis(Guardant (United States)), Kelly K. Hunt(The University of Texas MD Anderson Cancer Center), Jeremy Hoog(Washington University in St. Louis), Gary Unzeitig(Doctors Hospital of Laredo), Paula Silverman(Southwestern Medical Center), Pat W. Whitworth(Southwestern Medical Center), Katherine DeSchryver(Washington University in St. Louis), Gildy V. Babiera(The University of Texas MD Anderson Cancer Center), G. Thomas Budd(Cleveland Clinic), X. Cynthia(Washington University in St. Louis), Rodrigo Gonçalves(Southwestern Medical Center), Jingqin Luo(Washington University in St. Louis), Timothy Pluard(Southwestern Medical Center), Michael Barnes(Southwestern Medical Center), Chad J. Creighton(Baylor College of Medicine), Lisa A. Carey(University of North Carolina at Chapel Hill), Mitch Dowsett(Institute of Cancer Research), Souzan Sanati(Washington University in St. Louis), Eric P. Winer(University of Vermont), Laura J. Esserman(University of California, San Francisco), Amy Brink(Southwestern Medical Center), Vera J. Suman(Mayo Clinic in Arizona), Tao Yu(Washington University in St. Louis), Erika C. Crouch(Southwestern Medical Center), Marilyn Leitch(Harold C. Simmons Comprehensive Cancer Center), D. Craig Allred(The University of Texas Health Science Center at San Antonio), David M. Ota(Southwestern Medical Center), J. Michael Guenther(Good Samaritan Hospital), Zoneddy Dayao(University of New Mexico Hospital), John A. Olson(Vanderbilt University), Mark A. Watson(Washington University in St. Louis)
Cited by 411
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k